Chenguang Biotech Group (300138.SZ) issues a profit warning, expecting a net profit of 80-115 million yuan for the year, a year-on-year decrease of 76.03% to 83.32%.
Chen Guang Biology (300138.SZ) disclosed its 2024 performance forecast, and the company expects net profit attributable to shareholders of the listed company to...
Chenguang Biotech Group (300138.SZ) disclosed its performance forecast for 2024, with the company expecting a net profit attributable to shareholders of the listed company of 80 million to 115 million yuan, a year-on-year decrease of 76.03% to 83.32%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be 20 million to 55 million yuan, a year-on-year decrease of 85.02% to 94.55%.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
